Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics
PIRS Price/Volume Stats
Current price | $0.32 | 52-week high | $1.97 |
Prev. close | $0.33 | 52-week low | $0.16 |
Day low | $0.31 | Volume | 415,600 |
Day high | $0.33 | Avg. volume | 1,662,504 |
50-day MA | $0.28 | Dividend yield | N/A |
200-day MA | $0.85 | Market Cap | 31.63M |
PIRS Stock Price Chart Interactive Chart >
PIRS POWR Grades
- Sentiment is the dimension where PIRS ranks best; there it ranks ahead of 86.42% of US stocks.
- PIRS's strongest trending metric is Value; it's been moving down over the last 90 days.
- PIRS's current lowest rank is in the Growth metric (where it is better than 6.8% of US stocks).
PIRS Stock Summary
- Of note is the ratio of PIERIS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 8.75% of US stocks have a lower such ratio.
- In terms of volatility of its share price, PIRS is more volatile than 95.04% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PIRS comes in at -63.92% -- higher than that of only 8.63% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to PIERIS PHARMACEUTICALS INC, a group of peers worth examining would be SYBX, SPRB, SEEL, STTK, and SYRS.
- PIRS's SEC filings can be seen here. And to visit PIERIS PHARMACEUTICALS INC's official web site, go to www.pieris.com.
PIRS Valuation Summary
- In comparison to the median Healthcare stock, PIRS's EV/EBIT ratio is 99.19% lower, now standing at 0.1.
- PIRS's price/earnings ratio has moved up 6.6 over the prior 106 months.
Below are key valuation metrics over time for PIRS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PIRS | 2023-09-18 | 0.9 | 0.8 | -1.2 | 0.1 |
PIRS | 2023-09-15 | 0.9 | 0.8 | -1.1 | 0.1 |
PIRS | 2023-09-14 | 1.0 | 0.8 | -1.2 | 0.0 |
PIRS | 2023-09-13 | 1.0 | 0.8 | -1.2 | 0.0 |
PIRS | 2023-09-12 | 1.0 | 0.8 | -1.2 | 0.0 |
PIRS | 2023-09-11 | 0.9 | 0.8 | -1.2 | 0.1 |
PIRS Growth Metrics
- The year over year net cashflow from operations growth rate now stands at 57.66%.
- Its 2 year price growth rate is now at -43.71%.
- Its 5 year revenue growth rate is now at 760.34%.

The table below shows PIRS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 28.499 | -57.943 | -34.707 |
2022-06-30 | 27.186 | -63.649 | -41.507 |
2022-03-31 | 26.773 | -18.165 | -46.667 |
2021-12-31 | 31.418 | -7.66 | -45.738 |
2021-09-30 | 24.852 | -10.133 | -50.606 |
2021-06-30 | 23.734 | -3.219 | -48.353 |
PIRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PIRS has a Quality Grade of C, ranking ahead of 27.39% of graded US stocks.
- PIRS's asset turnover comes in at 0.193 -- ranking 490th of 561 Business Services stocks.
- NXTD, ATVI, and AEYE are the stocks whose asset turnover ratios are most correlated with PIRS.
The table below shows PIRS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.193 | 1 | -1.697 |
2021-03-31 | 0.279 | 1 | -0.852 |
2020-12-31 | 0.254 | 1 | -0.693 |
2020-09-30 | 0.359 | 1 | -0.373 |
2020-06-30 | 0.456 | 1 | -0.199 |
2020-03-31 | 0.398 | 1 | -0.367 |
PIRS Price Target
For more insight on analysts targets of PIRS, see our PIRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
Pieris Pharmaceuticals, Inc. (PIRS) Company Bio
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.
Latest PIRS News From Around the Web
Below are the latest news stories about PIERIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PIRS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning! |
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisUnpacking the Risks and Rewards of Investing in Pieris Pharmaceuticals |
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowPieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificPieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. |
Pieris lays off most staff after AstraZeneca pulls out of partnershipPieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale. |
PIRS Price Returns
1-mo | -25.58% |
3-mo | 29.55% |
6-mo | -75.48% |
1-year | -73.77% |
3-year | -84.76% |
5-year | -94.00% |
YTD | -69.23% |
2022 | -72.49% |
2021 | 51.20% |
2020 | -30.94% |
2019 | 36.09% |
2018 | -64.77% |
Continue Researching PIRS
Want to see what other sources are saying about Pieris Pharmaceuticals Inc's financials and stock price? Try the links below:Pieris Pharmaceuticals Inc (PIRS) Stock Price | Nasdaq
Pieris Pharmaceuticals Inc (PIRS) Stock Quote, History and News - Yahoo Finance
Pieris Pharmaceuticals Inc (PIRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...